Stock 719 SHANDONG XINHUA PHARMACEUTICAL COMPANY LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Shandong Xinhua Pharmaceutical Company Limited

Equities

719

CNE100000411

Market Closed - Hong Kong S.E.
Other stock markets
 09:08:22 10/05/2024 BST 		5-day change 1st Jan Change
5.78 HKD +2.12% Intraday chart for Shandong Xinhua Pharmaceutical Company Limited +4.71% 0.00%
04-25 Shandong Xinhua Pharmaceutical Company Limited Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
04-11 Xinhua Pharma Unit's Cefaclor Capsules Passes Regulatory Evaluation MT

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Shandong Xinhua Pharmaceutical Company Limited Reports Earnings Results for the First Quarter Ended March 31, 2024
Xinhua Pharma Unit's Cefaclor Capsules Passes Regulatory Evaluation
Shandong Xinhua Pharmaceutical Company Limited Receives Notification of Approval of Supplementary Drug Application
Shandong Xinhua Pharmaceutical Posts Higher 2023 Profit
Shandong Xinhua Pharmaceutical Proposes New Auditor
Shandong Xinhua Pharmaceutical Company Limited Proposes Final Dividend for the Year Ended 31 December 2023
Shandong Xinhua Pharmaceutical Company Limited Reports Earnings Results for the Full Year Ended December 31, 2023
Xinhua Pharma's Ibuprofen Gets Registration Approval in China
Shandong Xinhua Pharmaceutical Company Limited Receives Notification of Approval of Application for Marketing of Active Pharmaceutical Ingredient
Shandong Xinhua Pharmaceutical Company Limited Announces on Memantine Hydrochloride Tablets Obtaining the Drug Registration Certificate
Shandong Xinhua Pharmaceutical Company Limited Announces Executive Changes
Shandong Xinhua Pharmaceutical Gets Certificate for Registration of Levamlodiping Besylate Tablets
Shandong Xinhua Pharmaceutical Company Limited Receives Drug Registration Certificate of levamlodiping besylate tablets (2.5mg)
Respiratory Drug by Xinhua Pharmaceutical Unit Passes Regulatory Evaluation for Generic Drugs in China
Xinhua Pharmaceutical's Nine-Month Profit Jumps 34%
Shandong Xinhua Pharmaceutical Company Limited Reports Earnings Results for the Nine Months Ended September 30, 2023
Shandong Xinhua Pharmaceutical’s AntiCoagulant Tablets Get Drug Registration Certificate
China Grants Marketing Approval for Shandong Xinhua Pharmaceutical's Uric Acid Medication; Shares Rise 4%
Shandong Xinhua Pharmaceutical Company Limited Announces Approval of Marketing Application for Chemical Raw Material Drugs for Drugsof Febuxostat
Xinhua Pharmaceutical Unit's Clarithromycin Granules Passes Regulatory Evaluation
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 719 Stock
  4. News Shandong Xinhua Pharmaceutical Company Limited
  5. Other languages